The Human AccellDeubiquitinating Enzyme siRNA library targets members of the deubiquitinating enzyme group which remove ubiquitin. Protein ubiquitination controls many intracellular processes, including cell cycle progression, transcriptional activation, and signal transduction.
Accell siRNA achieves what no other RNAi product can claim: delivery into difficult-to-transfect cells without transfection reagents, virus, or electroporation. Researchers around the world are achieving targeted gene silencing in cells that had previously been beyond the reach of conventional RNAi products due to toxicity caused by transfection reagents or undesirable viral responses.
- Accell siRNA enters cells without the need for transfection reagents, virus (or viral vectors), or instruments
- Proven performance in neuronal, immunological, primary, and other difficult-to-transfect cell types
- Extended-duration knockdown with optimized continuous application
- Available as SMARTpool siRNA reagents or a Set of 4 siRNAs in 96 well plates
For a complete list of target genes in this siRNA Library, please email Technical Support, or call 1-800-235-9880. International customers, please call 303-604-9499 or your local Sales Representative.
- Accell siRNA works at a higher concentration than conventional siRNA; recommended 1 µM working concentration
- Delivery may be inhibited by the presence of BSA in serum. Optimization studies with serum-free media formulations (Accell Delivery Media) or < 2.5% serum in standard media is recommended
- Full-serum media can be added back after 48 hours of incubation. Optimal mRNA silencing is typically achieved by 72 hours or up to 96 hours for protein knockdown
Click to view a more comprehensive list of Accell siRNA citations.
- S. Suzuki et al., Differential Roles of Epac in Regulating Cell Death in Neuronal and Myocardial Cells. J. Biol. Chem. 285, 24248-24259 (July 2010). [primary mouse cortical neurons (E15-17)]
- U. Dreses-Werringloer et al., A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Ab Levels, and Alzheimer’s Disease Risk. Cell. 133, 1149-1161 (27 June 2008). [SHSY-5Y; human neuroblastoma]
- S. Byas et al., Human Embryonic Stem Cells Maintain Pluripotency after E-Cadherin Expression Knockdown. FASEB J. 24, lb172 (Apr 2010). [H9 stem cell lines]
- V. Saini et al, CXC Chemokine Receptor 4 Is a Cell Surface Receptor for Extracellular Ubiquitin. J. Biol. Chem. 285, 15566-15576 (May 2010). [THP-1 monocytes]
- D. Smirnov et al., Genetic Analysis of Radiation-induced Changes in Human Gene Expression. Nature. 459, 10.1038/nature07940(28 May 2009). [immortalized B cells]
|Storage Conditions||-20 C|
|Stability at Recommended Storage Conditions||At least 12 months|
Cell types demonstrating effective silencing with Accell siRNA
Internal validation and peer-reviewed publications report numerous successes with difficult-to-transfect cell types. See the Citations tab for a list of published references.
The Accell siRNA application protocol simplifies targeted gene knockdown
(1) Combine Accell siRNA with Accell delivery media (or other low- or no-serum media). (2) Add Accell delivery mix directly to cells, and incubate for 72 hours.